Review of epidemiology, diagnosis, and treatment of invasive mould infections in allogeneic hematopoietic stem cell transplant recipients

Mycopathologia

Volumn 162, Issue 1, 2006, Pages 1-15

  Bhatti, Zahida ^a   Shaukat, Aasma ^b   Almyroudis, Nikolaos G ^a   Segal, Brahm H ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aspergillus; Fusarium; Graft versus host disease; Mould; Stem cell transplant; Zygomycete

Indexed keywords

ANTIFUNGAL AGENT; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ASPERGILLOSIS; ASPERGILLUS; DRUG COMBINATION; FUSARIUM; GROWTH, DEVELOPMENT AND AGING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MICROBIOLOGY; MYCOSIS; REVIEW; SCEDOSPORIUM;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; DRUG THERAPY, COMBINATION; FUSARIUM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MYCOSES; PYRIMIDINES; SCEDOSPORIUM; TRIAZOLES;

ASPERGILLUS; FUSARIUM; FUSARIUM SP.; SCEDOSPORIUM; ZYGOMYCETES;

EID: 33745797267     PISSN: 0301486X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11046-006-0025-x     Document Type: Review

References (102)

1. TJ Walsh A Groll J Hiemenz R Fleming E Roilides E Anaissie 2004 Infections due to emerging and uncommon medically important fungal pathogens Clin Microbiol Infect 10 Suppl 1 48 66
2. BN Jahagirdar VA Morrison 2002 Emerging fungal pathogens in patients with hematologic malignancies and marrow/stem-cell transplant recipients Semin Respir Infect 17 2 113 120
3. KA Marr RA Carter F Crippa A Wald L Corey 2002 Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients Clin Infect Dis 34 7 909 917
4. L Romani 2004 Immunity to fungal infections Nat Rev Immunol 4 1 1 23
5. DA Stevens 2004 Vaccinate against aspergillosis! A call to arms of the immune system Clin Infect Dis 38 8 1131 1136 Epub 2004 Apr 5
6. BJ Kullberg AM Oude Lashof MG Netea 2004 Design of efficacy trials of cytokines in combination with antifungal drugs Clin Infect Dis 39 Suppl 4 S218 S223
7. BH Segal J Kwon-Chung TJ Walsh BS Klein M Battiwalla NG Almyroudis SM Holland L Romani 2006 Immunotherapy for fungal infections Clin Infect Dis 42 4 507 515
8. BH Segal TJ Walsh 2005 Current approaches to diagnosis and treatment of invasive aspergillosis Am J Respir Crit Care Med 173 707 717
9. CL Mackall RE Gress 1997 Pathways of T-cell regeneration in mice and humans: Implications for bone marrow transplantation and immunotherapy Immunol Rev 157 61 72
10. J Morgan KA Wannemuehler KA Marr S Hadley DP Kontoyiannis TJ Walsh SK Fridkin PG Pappas DW Warnock 2005 Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: Interim results of a prospective multicenter surveillance program Med Mycol 43 Suppl 1 S49 S58
11. A Wald W Leisenring JA van Burik RA Bowden 1997 Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation [see comments] J Infect Dis 175 6 1459 1466
12. JW Baddley TP Stroud D Salzman PG Pappas 2001 Invasive mold infections in allogeneic bone marrow transplant recipients Clin Infect Dis 32 9 1319 1324
13. WB Grow JS Moreb D Roque K Manion H Leather V Reddy SA Khan KJ Finiewicz H Nguyen CJ Clancy PS Mehta JR Wingard 2002 Late onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital Bone Marrow Transplant 29 1 15 19
14. E Jantunen P Ruutu L Niskanen L Volin T Parkkali P Koukila-Kahkola T Ruutu 1997 Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients Bone Marrow Transplant 19 8 801 808
15. PH [tmp] McWhinney CC Kibbler MD Hamon OP Smith L Gandhi LA Berger RK Walesby AV Hoffbrand HG Prentice 1993 Progress in the diagnosis and management of aspergillosis in bone marrow transplantation: 13 years' experience Clin Infect Dis 17 3 397 404
16. KY Yuen PC Woo MS Ip RH Liang EK Chiu H Siau PL Ho FF Chen TK Chan 1997 Stage-specific manifestation of mold infections in bone marrow transplant recipients: Risk factors and clinical significance of positive concentrated smears Clin Infect Dis 25 1 37 42
17. KA Marr RA Carter M Boeckh P Martin L Corey 2002 Invasive aspergillosis in allogeneic stem cell transplant recipients: Changes in epidemiology and risk factors Blood 100 13 4358 4366
18. A Shaukat F Bakri P Young T Hahn D Ball MR Baer M Wetzler JL Slack P Loud M Czuczman PL [tmp] McCarthy TJ Walsh BH Segal 2005 Invasive filamentous fungal infections in allogeneic hematopoietic stem cell transplant recipients after recovery from neutropenia: Clinical, radiologic, and pathologic characteristics Mycopathologia 159 2 181 188
19. T Fukuda M Boeckh RA Carter BM Sandmaier MB Maris DG Maloney PJ Martin RF Storb KA Marr 2003 Invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplantation after nonmyeloablative conditioning: Risks and outcomes Blood 10 10
20. Walsh TJ, Roden M, Nelson L, Knudsen T, Venzon D, Segal B, Barrett J, Childs R. Invasive Fungal Infections Complicating Non-Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT). ICAAC, 42nd meeting, San Diego, CA, 2002
21. EA Hagen H Stern D Porter K Duffy K Foley S Luger SJ Schuster EA Stadtmauer MG Schuster 2003 High rate of invasive fungal infections following nonmyeloablative allogeneic transplantation Clin Infect Dis 36 1 9 15
22. AR Alam G Varma T Hahn B Segal P Paplham J Becker M Baer B Bambach J Silva J Slack M Wetzler PL [tmp] McCarthy Jr 2002 Infectious complications in long-term survivors of cord blood stem cell transplantation (CBSCT): Experience at Roswell Park Cancer Institute Blood 100 629(s)
23. DW Denning P Ribaud N Milpied D Caillot R Herbrecht E Thiel A Haas M Ruhnke H Lode 2002 Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis Clin Infect Dis 34 5 563 571
24. TF Patterson WR Kirkpatrick M White JW Hiemenz JR Wingard B Dupont MG Rinaldi DA Stevens JR Graybill 2000 Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group Medicine (Baltimore) 79 4 250 260
25. R Herbrecht DW Denning TF Patterson JE Bennett RE Greene JW Oestmann WV Kern KA Marr P Ribaud O Lortholary R Sylvester RH Rubin JR Wingard P Stark C Durand D Caillot E Thiel PH Chandrasekar MR Hodges HT Schlamm PF Troke B de Pauw 2002 Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis N Engl J Med 347 6 408 415
26. T Fukuda M Boeckh RA Carter BM Sandmaier MB Maris DG Maloney PJ Martin RF Storb KA Marr 2003 Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning Blood 102 3 827 833
27. FM Marty SJ Lee MM Fahey EP Alyea RJ Soiffer JH Antin LR Baden 2003 Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors for non-Candida invasive fungal infections in allogeneic hematopoietic transplant recipients: A cohort study Blood 102 2768 2776
28. SG Filler MR Yeaman DC Sheppard 2005 Tumor necrosis factor inhibition and invasive fungal infections Clin Infect Dis 41 Suppl 3 S208 S212
29. F Crippa L Holmberg RA Carter H Hooper KA Marr W Bensinger T Chauncey L Corey M Boeckh 2002 Infectious complications after autologous CD34-selected peripheral blood stem cell transplantation Biol Blood Marrow Transplant 8 5 281 289
30. J Berenguer MC Allende JW Lee K Garrett C Lyman NM Ali J Bacher PA Pizzo TJ Walsh 1995 Pathogenesis of pulmonary aspergillosis. Granulocytopenia versus cyclosporine and methylprednisolone-induced immunosuppression Am J Respir Crit Care Med 152 3 1079 1086
31. Chamilos G, Luna M, Lewis RE, Safdar A, Bodey GP, Raad II, Kontoyiannis DP. Invasive fungal infections (IFIs) in patients (pts) with hematological malignancies (1989-2003): An autopsy study. 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2005: M-720
32. S Schwartz M Ruhnke P Ribaud L Corey T Driscoll OA Cornely U Schuler I Lutsar P Troke E Thiel 2005 Improved outcome in central nervous system aspergillosis, using voriconazole treatment Blood 106 8 2641 2645
33. DW Denning 1996 Therapeutic outcome in invasive aspergillosis Clin Infect Dis 23 3 608 615
34. TJ Walsh I Lutsar T Driscoll B Dupont M Roden P Ghahramani M Hodges AH Groll JR Perfect 2002 Voriconazole in the treatment of aspergillosis, scedosporiosis, and other invasive fungal infections in children Pediatr Infect Dis J 21 240 248
35. WJ Steinbach DK Benjamin Jr DP Kontoyiannis JR Perfect I Lutsar KA Marr MS Lionakis HA Torres H Jafri TJ Walsh 2004 Infections due to Aspergillus terreus: A multicenter retrospective analysis of 83 cases Clin Infect Dis 39 2 192 198 Epub 2004 Jun 28
36. J Maertens I Raad G Petrikkos M Boogaerts D Selleslag FB Petersen CA Sable NA Kartsonis A Ngai A Taylor TF Patterson DW Denning TJ Walsh 2004 Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy Clin Infect Dis 39 11 1563 1571. Epub 2004 Nov 9
37. CG Dennis WR Greco Y Brun R Youn HK Slocum RJ Bernacki R Lewis N Wiederhold SM Holland R Petraitiene TJ Walsh BH Segal 2006 Effect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47phox-/- mouse model of chronic granulomatous disease Antimicrob Agents Chemother 50 2 422 427
38. WR Kirkpatrick S Perea BJ Coco TF Patterson 2002 Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis Antimicrob Agents Chemother 46 8 2564 2568
39. V Petraitis R Petraitiene AA Sarafandi AM Kelaher CA Lyman HE Casler T Sein AH Groll J Bacher NA Avila TJ Walsh 2003 Combination therapy in treatment of experimental pulmonary aspergillosis: Synergistic interaction between an antifungal triazole and an echinocandin J Infect Dis 187 12 1834 1843
40. JC Luque KV Clemons DA Stevens 2003 Efficacy of micafungin alone or in combination against systemic murine aspergillosis Antimicrob Agents Chemother 47 1452 1455
41. PH Chandrasekar JL Cutright EK Manavathu 2004 Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive aspergillosis Clin Microbiol Infect 10 925 928
42. O Sivak K Bartlett V Risovic E Choo F Marra DS Batty KM Wasan 2004 Assessing the antifungal activity and toxicity profile of amphotericin B lipid complex (ABLC; Abelcet) in combination with caspofungin in experimental systemic aspergillosis J Pharm Sci 93 1382 1389
43. JR Graybill R Bocanegra GM Gonzalez LK Najvar 2003 Combination antifungal therapy of murine aspergillosis: Liposomal amphotericin B and micafungin J Antimicrob Chemother 52 656 662
44. TB Aliff PG Maslak JG Jurcic ML Heaney KN Cathcart KA Sepkowitz MA Weiss 2003 Refractory Aspergillus pneumonia in patients with acute leukemia: Successful therapy with combination caspofungin and liposomal amphotericin Cancer 97 4 1025 1032
45. DP Kontoyiannis R Hachem RE Lewis GA Rivero HA Torres J Thornby R Champlin H Kantarjian GP Bodey II Raad 2003 Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies Cancer 98 2 292 299
46. KA Marr M Boeckh RA Carter HW Kim L Corey 2004 Combination antifungal therapy for invasive aspergillosis Clin Infect Dis 39 6 797 802 Epub 2004 Aug 27
47. Maertens J, Glasmacher A, Herbrecht R, Aoun M, Thiebaut A, Cordonnier C, Segal B, Caillot D, Sable C, Killar J, Taylor A, Kartsonis, Patterson T. Multicenter, noncomparative study of caspofungin (CAS) combined with other antifungals in adults with invasive aspergillosis (IA) refractory (R) or intolerant (I) to prior therapy (rx): Final data. 45th annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2005 (abstract M-954)
48. Raad I, S. Chapman, R. Bradsher, V. Morrison, M. Goldman, J. Graybill, J. R. Perfect, T. Patterson, T. Walsh, G. Corcoran, and P. Pappas. 2004. Posaconazole (POS) salvage therapy for invasive fungal infections. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC (M-669)
49. F Offner C Cordonnier P Ljungman HG Prentice D Engelhard D De Bacquer F Meunier B De Pauw 1998 Impact of previous aspergillosis on the outcome of bone marrow transplantation Clin Infect Dis 26 5 1098 1103
50. T Fukuda M Boeckh KA Guthrie DK Mattson S Owens A Wald BM Sandmaier L Corey RF Storb KA Marr 2004 Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center Biol Blood Marrow Transplant 10 7 494 503
51. A Imhof SA Balajee DN Fredricks JA Englund KA Marr 2004 Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole Clin Infect Dis 39 5 743 746 Epub 2004 Aug 13
52. Marty FM, Cosimi L, Marasco WA, Rubin RH, Baden LR. Breakthrough zygomycosis in allogeneic hematopoietic stem cell transplant recipients who received voriconazole as prophylaxis or empiric therapy. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL. M-985, 2003
53. DP Kontoyiannis MS Lionakis RE Lewis G Chamilos M Healy C Perego A Safdar H Kantarjian R Champlin TJ Walsh II Raad 2005 Zygomycosis in a tertiary care cancer center in the era of Aspergillus-active antifungal therapy: A case control observational study of 27 recent cases J Infect Dis 191 1350 1360
54. DP Kontoyiannis VC Wessel GP Bodey KV Rolston 2000 Zygomycosis in the 1990s in a tertiary-care cancer center Clin Infect Dis 30 6 851 856
55. MM Roden TE Zaoutis WL Buchanan TA Knudsen TA Sarkisova RL Schaufele M Sein T Sein CC Chiou JH Chu DP Kontoyiannis TJ Walsh 2005 Epidemiology and outcome of zygomycosis: a review of 929 reported cases Clin Infect Dis 41 5 634 653
56. RN Greenberg K Mullane JA van Burik I Raad MJ Abzug G Anstead R Herbrecht A Langston KA Marr G Schiller M Schuster JR Wingard CE Gonzalez SG Revankar G Corcoran RJ Kryscio R Hare 2006 Posaconazole as salvage therapy for zygomycosis Antimicrob Agents Chemother 50 1 126 133
57. D.P. Kontoyiannis, R. Hare, H. Solomon, M. Corrado, and J. A. van Burik. 2005. Posaconazole is highly effective as a second-line agent in zygomycosis: summary of 91 cases. 45th annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, M-974
58. EI Boutati EJ Anaissie 1997 Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management Blood 90 3 999 1008
59. EJ Anaissie RT Kuchar JH Rex A Francesconi M Kasai FM Muller M Lozano-Chiu RC Summerbell MC Dignani SJ Chanock TJ Walsh 2001 Fusariosis associated with pathogenic fusarium species colonization of a hospital water system: a new paradigm for the epidemiology of opportunistic mold infections Clin Infect Dis 33 11 1871 1878
60. I Raad J Tarrand H Hanna M Albitar E Janssen M Boktour G Bodey M Mardani R Hachem D Kontoyiannis E Whimbey K Rolston 2002 Epidemiology, molecular mycology, and environmental sources of Fusarium infection in patients with cancer Infect Control Hosp Epidemiol 23 9 532 537
61. M Nucci KA Marr F Queiroz-Telles CA Martins P Trabasso S Costa JC Voltarelli AL Colombo A Imhof R Pasquini A Maiolino CA Souza E Anaissie 2004 Fusarium infection in hematopoietic stem cell transplant recipients Clin Infect Dis 38 9 1237 1242 Epub 2004 Apr 15
62. JR Perfect KA Marr TJ Walsh RN Greenberg B DuPont J de la Torre-Cisneros G Just-Nubling HT Schlamm I Lutsar A Espinel-Ingroff E Johnson 2003 Voriconazole treatment for less-common, emerging, or refractory fungal infections Clin Infect Dis 36 9 1122 1131
63. HA Torres RY Hachem RF Chemaly DP Kontoyiannis Raad II 2005 Posaconazole: a broad-spectrum triazole antifungal Lancet Infect Dis 5 12 775 785
64. JR Perfect 2005 Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex Clin Infect Dis 40 Suppl 6 S401 S408
65. DP Kontoyiannis GP Bodey H Hanna R Hachem M Boktour E Girgaway M Mardani Raad II 2004 Outcome determinants of fusariosis in a tertiary care cancer center: the impact of neutrophil recovery Leuk Lymphoma 45 1 139 141
66. F Silveira M Nucci 2001 Emergence of black moulds in fungal disease: epidemiology and therapy Curr Opin Infect Dis 14 679 684
67. SJ Levine 1992 An approach to the diagnosis of pulmonary infections in immunosuppressed patients Semin Respir Infect 7 2 81 95
68. R Greene 2004 The Radiologic Spectrum of Pulmonary Aspergillosis. Advances Against Aspergillosis San Francisco San Francisco, CA
69. JE Kuhlman EK Fishman PA Burch JE Karp EA Zerhouni SS Siegelman 1987 Invasive pulmonary aspergillosis in acute leukemia. The contribution of CT to early diagnosis and aggressive management Chest 92 95 99
70. D Caillot O Casasnovas A Bernard JF Couaillier C Durand B Cuisenier E Solary F Piard T Petrella A Bonnin G Couillault M Dumas H Guy 1997 Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery J Clin Oncol 15 1 139 147
71. D Caillot JF Couaillier A Bernard O Casasnovas DW Denning L Mannone J Lopez G Couillault F Piard O Vagner H Guy 2001 Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia J Clin Oncol 19 1 253 259
72. J Maertens J Verhaegen K Lagrou J Van Eldere M Boogaerts 2001 Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation Blood 97 6 1604 1610
73. J Maertens J Van Eldere J Verhaegen E Verbeken J Verschakelen M Boogaerts 2002 Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients J Infect Dis 186 9 1297 1306
74. R Herbrecht V Letscher-Bru C Oprea B Lioure J Waller F Campos O Villard KL Liu S Natarajan-Ame P Lutz P Dufour JP Bergerat E Candolfi 2002 Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients J Clin Oncol 20 7 1898 1906
75. LJ Wheat 2003 Rapid diagnosis of invasive aspergillosis by antigen detection Transpl Infect Dis 5 4 158 166
76. MA Mennink-Kersten JP Donnelly PE Verweij 2004 Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis Lancet Infect Dis 4 6 349 357
77. KA Marr SA Balajee L [tmp] McLaughlin M Tabouret C Bentsen TJ Walsh 2004 Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance J Infect Dis 190 3 641 649. Epub 2004 Jul 1
78. KA Marr M Laverdiere A Gugel W Leisenring 2005 Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay Clin Infect Dis 40 1762 1769
79. A Sulahian S Touratier P Ribaud 2003 False positive test for Aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam N Engl J Med 349 2366 2367
80. TJ Walsh S Shoham R Petraitiene T Sein R Schaufele A Kelaher H Murray C Mya-San J Bacher V Petraitis 2004 Detection of galactomannan antigenemia in patients receiving piperacillin-tazobactam and correlations between in vitro, in vivo, and clinical properties of the drug-antigen interaction J Clin Microbiol 42 10 4744 4748
81. Z Odabasi G Mattiuzzi E Estey H Kantarjian F Saeki RJ Ridge PA Ketchum MA Finkelman JH Rex L Ostrosky-Zeichner 2004 beta-d-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome Clin Infect Dis 39 2 199 205. Epub 2004 Jun 28
82. Ostrosky-Zeichner L, Alexander BD, Kett DH, et al. Multicenter clinical evaluation of the (1→3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005; 41: 654-659
83. Hachem RY, Boktour M, Daugherty T, Pham-Williams T, Warneke C, Chemaly RF, Raad II. The utillity of galactomannan enzyme immunoassay (GM-EIA) and (1,3) B-d-glucan (BD) in the diagnosis of invasive fungal infections in cancer patients. 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2005 (abstract M-161)
84. JH van Burik W Leisenring D Myerson RC Hackman HM Shulman GE Sale RA Bowden GB [tmp] McDonald 1998 The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. An autopsy study of 355 patients Medicine (Baltimore) 77 4 246 254
85. JA van Burik V Ratanatharathorn DE Stepan CB Miller JH Lipton DH Vesole N Bunin DA Wall JW Hiemenz Y Satoi JM Lee TJ Walsh 2004 Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation Clin Infect Dis 39 10 1407 1416
86. KA Marr F Crippa W Leisenring M Hoyle M Boeckh SA Balajee WG Nichols B Musher L Corey 2003 Itraconazole versus fuconazole for prevention of fungal infections in allogeneic stem cell transplant patients Blood 2 2
87. DJ Winston RT Maziarz PH Chandrasekar HM Lazarus M Goldman JL Blumer GJ Leitz MC Territo 2003 Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial Ann Intern Med 138 9 705 713
88. KA Marr W Leisenring F Crippa JT Slattery L Corey M Boeckh GB [tmp] McDonald 2003 Cyclophosphamide metabolism is impacted by azole antifungals Blood 22 22
89. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo S, Greinix H, Azevedo W, Reddy V, Hardalo C, Patino H, Durrant S. Posaconazole (POS) vs. fluconazole (FLU) for prophylaxis for invasive fungal infections (IFIs) in allogeneic hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD): Results of a multicenter trial. 45th annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2005 (abstract M-716)
90. J Maertens K Theunissen G Verhoef J Verschakelen K Lagrou E Verbeken A Wilmer J Verhaegen M Boogaerts J Van Eldere 2005 Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: A prospective feasibility study Clin Infect Dis 41 9 1242 1250
91. JH Rex PG Pappas AW Karchmer J Sobel JE Edwards S Hadley C Brass JA Vazquez SW Chapman HW Horowitz M Zervos D [tmp] McKinsey J Lee T Babinchak RW Bradsher JD Cleary DM Cohen L Danziger M Goldman J Goodman E Hilton NE Hyslop DH Kett J Lutz RH Rubin WM Scheld M Schuster B Simmons DK Stein RG Washburn L Mautner TC Chu H Panzer RB Rosenstein J Booth 2003 A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects Clin Infect Dis 36 10 1221 1228
92. BJ Kullberg JD Sobel M Ruhnke PG Pappas C Viscoli JH Rex JD Cleary E Rubinstein LW Church JM Brown HT Schlamm IT Oborska F Hilton MR Hodges 2005 Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial Lancet 366 9495 1435 1442
93. DA Stevens JY Lee 1997 Analysis of compassionate use itraconazole therapy for invasive aspergillosis by the NIAID Mycoses Study Group criteria Arch Int Med 157 16 1857 1862
94. Cornely OA, Maertens J, Winston DJ, Perfect J, Helfgott D, Ullmann AJ, Angulo D. Posaconazole (POS) vs standard azoles as antifungal prophylaxis in neutropenic patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS): Impact on mortality. Abstract 722-b. 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2005
95. TJ Walsh RW Finberg C Arndt J Hiemenz C Schwartz D Bodensteiner P Pappas N Seibel RN Greenberg S Dummer M Schuster JS Holcenberg 1999 Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group N Engl J Med 340 10 764 771
96. JR Wingard MH White E Anaissie J Raffalli J Goodman A Arrieta 2000 A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group Clin Infect Dis 31 5 1155 1163
97. PH Chandrasekar JI Ito 2005 Amphotericin B lipid complex in the management of invasive aspergillosis in immunocompromised patients Clin Infect Dis 40 Suppl 6 S392 S400
98. R Bowden P Chandrasekar MH White X Li L Pietrelli M Gurwith JA van Burik M Laverdiere S Safrin JR Wingard 2002 A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients Clin Infect Dis 35 4 359 366. Epub 2002 Jul 25
99. J Mora-Duarte R Betts C Rotstein AL Colombo L Thompson-Moya J Smietana R Lupinacci C Sable N Kartsonis J Perfect 2002 Comparison of caspofungin and amphotericin B for invasive candidiasis N Engl J Med 347 25 2020 2029
100. TJ Walsh H Teppler GR Donowitz JA Maertens LR Baden A Dmoszynska OA Cornely MR Bourque RJ Lupinacci CA Sable BE dePauw 2004 Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia N Engl J Med 351 14 1391 1402
101. Ruhnke M, Kuse E, Chetchotisakd P, Arns Da Cunha C, Diekmann-Berndt H. Comparison of micafungin and liposomal amphotericin B for invasive candidiasis. 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2005 (Abstract M-722c)
102. Reboli A, Rotstein C, Pappas P, Schranz J, Krause D, and Walsh T. Anidulafungin vs. fluconazole for treatment of candidemia and invasive candidiasis (C/IC). 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2005 (abstract M-718)